Infection par le virus respiratoire nosocomial (NOSOVIRUS)
Infection virale respiratoire nosocomiale : une étude prospective multicentrique en France
Hospital-acquired Viral Respiratory Infections (HAVRI) are associated with substantial burden on health care systems. The prevention and control of these viral infections rely on multiple measures such as hand hygiene or wearing mask. However, vaccination remains the major preventive measure.
To date, data at French national level are insufficient to describe the epidemiology of these infections, including their burden, and the potential protection of patients if vaccination coverage of health care professionals/patients is satisfactory. In addition, better understanding of the clinical characteristics of HAVRI will make it possible to identify potential sources of transmission as soon as possible and to implement appropriate hygiene measures.
We will set up a hospital-based prospective multicenter study in Bordeaux, Paris-Bichat, Dijon and Lyon, involving four inclusion services (geriatrics, internal medicine and transplantation) per hospital.
The main objective of this study is to calculate the incidence rate of hospital-acquired infections for three respiratory viruses; influenza, SARS-CoV-2 and syncytial respiratory virus (SRV), referred to as HARVI, in participating services.
Volunteered health care professionals or hospitalized patients presenting with influenza-like illness (ILI) at admission or during their stay in the participating centers will be eligible to be enrolled during the two inclusion periods: (mid-October 2024 to mid-April 2025 and mid-October 2025 to mid-April 2026).
For each patient/health care professional, a nasopharyngeal swab will be collected. A questionnaire including demographic data, medical history, vaccination, and clinical and biological data of the viral episode will also be completed by the study team. Patients tested positive for one of the viruses studied will be considered "cases" and patients tested negative as "controls".
The collected data will be pseudonymized before statistical analyses. Statistical analyses will consist of calculating incidence rates, attack rates overall and by causative virus and analysis of factors associated with the occurrence of HARVI.
The prospective design of the study will optimize the quality of the collected data (ex. consolidate the documentation of both the clinical picture and vaccination in patients and health care professionals by reducing memory bias) and allow to calculate the incidence rates, the crude and adjusted relative risks of HARVI according to the studied factors, and to describe multiple outcomes (hospitalization in intensive care units, death, etc.) based on the causative virus.
The results of this research project will allow to:
- obtain epidemiological indicators associated with HARVI;
- estimate the impact of HARVI on the prognosis of patients in hospital;
- assess the impact of HARVI on the total length of hospital stay;
- identify risk factors associated with HARVI;
- use the results as an argument for vaccination in order to increase vaccination coverage of healthcare workers.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Philippe VANHEMS, MD, PhD
- Numéro de téléphone: +33 4 72 11 07 20
- E-mail: Philippe.vanhems@chu-lyon.fr
Sauvegarde des contacts de l'étude
- Nom: Mitra SAADATIAN-ELAHI
- Numéro de téléphone: +33 4 72 11 07 18
- E-mail: Mitra.elahi@chu-lyon.fr
Lieux d'étude
-
-
-
Bordeaux, France, 33076
- Pas encore de recrutement
- Pellegrin Hospital
-
Contact:
- Anne Marie ROGUES, Professor
- Numéro de téléphone: +33 5 56 79 55 53
- E-mail: anne-marie.rogues@chu-bordeaux.fr
-
Chercheur principal:
- Anne Marie ROGUES, Professor
-
Dijon, France, 21079
- Pas encore de recrutement
- CHU Dijon
-
Contact:
- Ludwig Serge AHO-GLELE, Professor
- Numéro de téléphone: +33 3 80 29 38 01
- E-mail: ludwig.aho@chu-dijon.fr
-
Chercheur principal:
- Ludwig Serge AHO-GLELE, professor
-
Lyon, France, 69003
- Recrutement
- Edouard Herriot Hospital
-
Contact:
- Philippe VANHEMS, Professor
- Numéro de téléphone: +33 4 72 11 07 20
- E-mail: Philippe.vanhems@chu-lyon.fr
-
Chercheur principal:
- Philippe VANHEMS, Professor
-
Paris, France
- Pas encore de recrutement
- Saint Louis Hospital
-
Contact:
- Nathalie DE CASTRO, Dr
- Numéro de téléphone: 01 42 49 48 20
- E-mail: nathalie.de-castro@aphp.fr
-
Paris, France, 75877
- Pas encore de recrutement
- Bichat Hospital
-
Contact:
- Solen KERNEIS, Professor
- Numéro de téléphone: +33 1 40 25 60 59
- E-mail: solen.kerneis@aphp.fr
-
Chercheur principal:
- Solen KERNEIS, professor
-
Paris, France, 75010
- Pas encore de recrutement
- Saint Louis Hospital
-
Contact:
- Guillaume MELLON, Dr
- Numéro de téléphone: 01 42 49 44 97
- E-mail: guillaume.mellon@aphp.fr
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults> 18 years old
- Hospitalized patient or health care professionals presenting an ILI on admission or during the stay, meeting the following definition: fever greater than 37.8° C in the absence of taking antipyretics and/or cough or pharyngeal pain.
- Signed consent form
Exclusion Criteria:
- Pregnant, parturient or breastfeeding women
- individuals deprived of their liberty by a judicial or administrative decision
- Individuals subject to psychiatric care
- Individuals admitted to a health or social establishment for purposes other than research
- Individuals under a legal protection measure (guardianship, curatorship)
- Individuals not affiliated to a social security insurance
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Autre: Patients hospitalized in participating services for more than 24h
Patients hospitalized for more than 24 hours in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) on admission or during hospital stay are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF. |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
|
Autre: Volunteered health care professionals
Volunteered health care professionals in the participating services (geriatric, internal medicine, transplantation) and who presents an influenza like illness (ILI) are eligible to participate. Following the signature of the consent, nasopharyngeal sample will be collected. Socio-demographic (questionnaire) and clinical information will be obtained using the study e-CRF |
Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant. questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of hospital-acquired respiratory viral infections
Délai: At inclusion
|
The primary endpoint will be evaluated by calculating the incidence of hospital-acquired respiratory viral infections overall and by type of virus (influenza, COVID-19, RSV) during the surveillance period. incidence rate will be estimated by the ration of number of incident cases over the study period to the cumulative observation time (in person-weeks) of hospitalized patients. Incidence density will be estimated by the ratio of number of incident cases during successive weekly observation periods to the cumulative observation times calculated over the same periods. |
At inclusion
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Attributs de la maladie
- Infections des voies respiratoires
- Infections
- Infections à Orthomyxoviridae
- Infections par virus à ARN
- Maladies virales
- Maladies des voies respiratoires
- Maladies pulmonaires
- Pneumonie virale
- Pneumonie
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Maladie iatrogène
- Conditions pathologiques, signes et symptômes
- COVID-19 [feminine]
- Grippe humaine
- Infection croisée
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Méthodes épidémiologiques
- Collecte de données
- Mécanismes d'évaluation des soins de santé
- Qualité des soins de santé
- Santé publique
- Environnement et santé publique
- Enquêtes et questionnaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 69HCL23_1091
- 2024-A01267-40 (Autre identifiant: ID-RCB)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .